{"id":21581,"date":"2026-05-08T06:26:27","date_gmt":"2026-05-08T10:26:27","guid":{"rendered":"https:\/\/www.purdue.edu\/newsroom\/?p=21581"},"modified":"2026-05-08T08:49:51","modified_gmt":"2026-05-08T12:49:51","slug":"amplified-sciences-enrolls-patients-in-panamp-real-world-multicenter-clinical-utility-study","status":"publish","type":"post","link":"https:\/\/www.purdue.edu\/newsroom\/2026\/Q2\/amplified-sciences-enrolls-patients-in-panamp-real-world-multicenter-clinical-utility-study","title":{"rendered":"Amplified Sciences enrolls patients in PanAMP real-world, multicenter clinical utility study"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">WEST LAFAYETTE, Ind. \u2014 <a href=\"https:\/\/amplifiedsciences.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Amplified Sciences<\/a>, a diagnostics life sciences company revolutionizing early disease detection, announced Friday (May 8) the launch of PanAMP, a clinical utility study for its PanCystPro assay.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This real-world, multicenter study in patients with radiographically confirmed pancreatic cysts aims to assess the impact of the company\u2019s PanCystPro assay on healthcare providers\u2019 patient management decisions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Amplified Sciences CEO Diana Caldwell said PanCystPro helps risk-stratify patients with a known precursor for pancreatic cancer \u2014 those diagnosed with pancreatic cystic lesions, which represent a window to earlier detection of the cancer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cThese cystic lesions are a challenge for many clinicians, and the use of innovative tests like PanCystPro alongside imaging can provide insights on surveillance and treatment strategies for those patients at higher risk for pancreatic cancer,\u201d Caldwell said.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Principal investigators of the PanAMP study are:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Dr. Mohammad Al-Haddad, Indiana University School of Medicine, Indianapolis<\/li>\n\n\n\n<li>Dr. Srinivas Gaddam, Cedars-Sinai Medical Center, Los Angeles<\/li>\n\n\n\n<li>Dr. Mandeep Sawhney, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston<\/li>\n\n\n\n<li>Dr. Arvind Trindade, Rutgers Health and RWJBarnabas Health, New Brunswick, New Jersey<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cPancreatic cystic lesion management remains one of the most challenging areas in our daily practice due to persistent diagnostic uncertainty,\u201d Al-Haddad said. \u201cIncorporating an accurate low-volume test like PanCystPro into the diagnostics workflow has the potential to provide clinicians with more actionable information to determine surveillance frequency and treatment strategies.\u201d<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Amplified Sciences and Purdue University<\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"400\" src=\"https:\/\/www.purdue.edu\/newsroom\/wp-content\/uploads\/2026\/05\/amplifiedsciences-davisson-caldwell.jpg\" alt=\"V. Jo Davisson and Diana Caldwell stand together in front of laboratory equipment.\" class=\"wp-image-21579\" title=\"\" srcset=\"https:\/\/www.purdue.edu\/newsroom\/wp-content\/uploads\/2026\/05\/amplifiedsciences-davisson-caldwell.jpg 300w, https:\/\/www.purdue.edu\/newsroom\/wp-content\/uploads\/2026\/05\/amplifiedsciences-davisson-caldwell-225x300.jpg 225w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><figcaption class=\"wp-element-caption\">Purdue University researcher V. Jo Davisson and CEO Diana Caldwell are the founders of Amplified Sciences, a life sciences diagnostic company. (Purdue Research Foundation photo\/Jennifer Mayberry)<\/figcaption><\/figure>\n<\/div>\n\n\n<p class=\"wp-block-paragraph\">Amplified Sciences\u2019 optical reporter system, BioMatra, and suite of diagnostic tests are based on innovative technology invented by <a href=\"https:\/\/www.mcmp.purdue.edu\/faculty\/davisson\" target=\"_blank\" rel=\"noreferrer noopener\">V. Jo Davisson<\/a>, chief scientific officer of Amplified Sciences, professor of medicinal chemistry and molecular pharmacology in Purdue University\u2019s <a href=\"https:\/\/www.pharmacy.purdue.edu\/\" target=\"_blank\" rel=\"noreferrer noopener\">College of Pharmacy<\/a>, and an affiliated faculty member of the <a href=\"https:\/\/www.purdue.edu\/cancer-research\/index.php\" target=\"_blank\" rel=\"noreferrer noopener\">Purdue Institute for Cancer Research<\/a> and the <a href=\"https:\/\/www.purdue.edu\/discoverypark\/drug-discovery\/\" target=\"_blank\" rel=\"noreferrer noopener\">Purdue Institute for Drug Discovery<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">He disclosed the intellectual property through the <a href=\"https:\/\/purdueinnovates.org\/otc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Purdue Innovates Office of Technology Commercialization<\/a>. OTC executed an exclusive license with Amplified Sciences for the global suite of patents.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Amplified Sciences is a <a href=\"https:\/\/strategicventures.prf.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">Purdue Innovates Ventures<\/a> portfolio company. Ventures most recently supported Amplified Sciences with an investment in the company\u2019s $2.6 million Series Seed Preferred capital raise in 2023.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">About Amplified Sciences<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Amplified Sciences is a life science diagnostics company focused on providing innovative diagnostic tests that enable earlier detection, risk stratification and monitoring of serious diseases. BioMatra\u2122, the company\u2019s ultrasensitive optical reporter platform, leverages technology licensed from Purdue University. Its headquarters is in West Lafayette, Indiana, and the CLIA-CAP accredited clinical lab is located in Irvine, California. To learn more about Amplified Sciences, visit <a href=\"https:\/\/amplifiedsciences.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">amplifiedsciences.com<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">About Purdue Innovates Office of Technology Commercialization<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The <a href=\"https:\/\/purdueinnovates.org\/otc\/\" data-type=\"link\" data-id=\"https:\/\/purdueinnovates.org\/otc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Purdue Innovates Office of Technology Commercialization<\/a> operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university\u2019s academic activities through commercializing, licensing and protecting Purdue intellectual property. In fiscal year 2025, the office reported 161 deals executed with 269 technologies licensed, 479 invention disclosures received, and 267 U.S. and international patents received. The office is managed by the Purdue Research Foundation, a private, nonprofit foundation created to advance the mission of Purdue University. Contact <a href=\"mailto:otcip@prf.org\">otcip@prf.org<\/a> for more information.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">About Purdue University<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Purdue University is a public research university leading with excellence at scale. Ranked among top 10 public universities in the United States, Purdue discovers, disseminates and deploys knowledge with a quality and at a scale second to none. More than 106,000 students study at Purdue across multiple campuses, locations and modalities, including more than 57,000 at our main campus locations in West Lafayette and Indianapolis. Committed to affordability and accessibility, Purdue\u2019s main campus has frozen tuition 14 years in a row. See how Purdue never stops in the persistent pursuit of the next giant leap \u2014 including its integrated, comprehensive Indianapolis urban expansion; the Mitch Daniels School of Business; Purdue Computes; and the One Health initiative \u2014 at <a href=\"https:\/\/www.purdue.edu\/president\/strategic-initiatives\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.purdue.edu\/president\/strategic-initiatives<\/a>.<\/p>\n\n\n<div id=\"note\" class=\"post-content__attribution \">\n    <div class=\"columns\"> \n                    <div class=\"column\"> \n                <p class=\"post-content__source\">\n                    <strong>Media contacts:<\/strong> Diana Caldwell, <a href=\"mailto:diana.caldwell@amplifiedsci.com\">diana.caldwell@amplifiedsci.com<\/a>; Steve Martin, <a href=\"mailto:sgmartin@prf.org\">sgmartin@prf.org<\/a>                <\/p>\n            <\/div>\n                    <\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>WEST LAFAYETTE, Ind. \u2014 Amplified Sciences, a diagnostics life sciences company revolutionizing early disease detection, announced Friday (May 8) the launch of PanAMP, a clinical utility study for its PanCystPro assay. This real-world, multicenter study in patients with radiographically confirmed<\/p>\n","protected":false},"author":25,"featured_media":21577,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[316],"tags":[],"department":[],"source":[35],"purdue_today_topic":[],"coauthors":[44],"class_list":["post-21581","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-prf","source-purdue-research-foundation"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts\/21581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/comments?post=21581"}],"version-history":[{"count":7,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts\/21581\/revisions"}],"predecessor-version":[{"id":21619,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts\/21581\/revisions\/21619"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/media\/21577"}],"wp:attachment":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/media?parent=21581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/categories?post=21581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/tags?post=21581"},{"taxonomy":"department","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/department?post=21581"},{"taxonomy":"source","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/source?post=21581"},{"taxonomy":"purdue_today_topic","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/purdue_today_topic?post=21581"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/coauthors?post=21581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}